Bibliografía
1. Hogan RB, Johnston JH, Long BW, et al. A double-blind, randomized, sham-controlled trial of the gastric bubble for obesity. Gastrointest Endosc 1989; 35:381-5.
2. Schapiro M, Benjamin S, Blackburn G, et al. Obesity and the gastric balloon: a comprehensive workshop. Tarpon Springs, Florida, March 19-21, 1987. Gastrointest Endosc 1987; 33: 323-7.
3. Genco A, López-Nava G, Wahlen C, et al. Multi-centre European experience with intragastric balloon in overweight populations: 13 years of experience. Obes Surg 2013; 23(4): 515-21.
4. Moura D, Oliveira J, De Moura EG, et al. .Effectiveness of intragastric balloon for obesity: A systematic review and meta-analysis based on randomized control trials. Surg Obes Relat Dis 2016; 12(2):420-9.
5. Martínez MÁ, Cancer E, Bretón I, et al. Intragastric balloon: a review concerning alternative balloons compared to the classical ones (bioenterics). Nutr Hosp 2014; 31(1): 84-91.
6. Espinet-Coll E, Nebreda-Durán J, Gómez-Valero JA, et al. Current endoscopic techniques in the treatment of obesity. Rev Esp Enferm Dig 2012; 104(2): 72-87.
7. Abu-Dayyeh BK, Sarmiento R, Rajan E, et al. Endoscopic treatments of obesity and metabolic disease: Are we there yet? Rev Esp Enferm Dig 2014; 106: 467-476.
8. Tsesmeli N, Coumaros D. Review of endoscopic devices for weight reduction: old and new balloons and implantable prostheses. Endoscopy 2009; 41(12): 1082-9.
9. Totte E, Hendrickx L, Pauwels M, et al. Weight reduction by means of intragastric device: experience with the bioenterics intragastric balloon. Obes Surg 2001; 11: 519-23.
10. Bonazzi P, Petrelli MD, Lorenzini I, et al. Gastric emptying and intragastric balloon in obese patients. Eur Rev Med Pharmacol Sci 2005; 9: 15-21.
11. Mathus-Vliegen EM, Tytgat G. Intragastric balloon for treatment resistant obesity: Safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc 2005; 61: 19-27.
12. Genco A, Cipriano M, Bacci V, et al. Intragastric balloon followed by diet vs intragastric balloon followed by another balloon: A prospective study on 100 patients. Obes Surg 2010; 20: 1496-500.
13. López-Nava G, Rubio MA, Prados S, et al. Bioenterics intragastric balloon. Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. Obes Surg 2011; 21(1): 5-9.
14. Peker Y, Durak E, Ozgurbuz U. Intragastric balloon treatment for obesity: prospective single-center study findings. Obes Facts 2010; 3: 105-8.
15. Stimac D, Majanovic SK, Turk T, et al. Intragastric balloon treatment for obesity: results of a large single center prospective study. Obes Surg 2011; 21: 551-5.
16. Farina MG, Baratta R, Nigro A, et al. Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity. Obes Surg 2012; 22: 565-71.
17. Fuller NR, Pearson S, Lau NS, et al. An intragastric balloon in the treatment of obese individuals with metabolic syndrome: A randomized controlled study. Obesity 2013; 21: 1561-70.
18. Mathus-Vliegen EM, Eichenberger RI. Fasting and meal-suppressed ghrelin levels before and after intragastric balloons and balloon-induced weight loss. Obes Surg 2014; 24: 85-94.
19. Gaur S, Levy S, Mathus-Vliegen L, et al. Balancing risk and reward: a critical review of the intragastric balloon for weight loss. Gastrointest Endosc 2015; 81(6): 1330-6.
20. Dumonceau JM. Evidence-based review of the Bioenterics intragastric balloon for weight loss. Obes Surg 2008; 18(12): 1611-7.
21. Kotzampassi K, Grosomanidis V, Papakostas P, et al. 500 intragastric balloons: what happens 5 years thereafter?. Obes Surg 2012; 22(6): 896-903.
22. Angrisani L, Lorenzo M, Borrelli V, et al. Is bariatric surgery necessary after intragastric balloon treatment?. Obes Surg 2006; 16(9): 1135-7.
23. Crea N, Pata G, Della Casa D, et al. Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg 2009; 19: 1084-8.
24. Ponce J, Quebbemann BB, Patterson EJ. Prospective, randomized, multicenter study evaluating safety and efficacy of intragastric dual-balloon in obesity. Surg Obes Relat Dis 2013; 9(2): 290-5.
25. Ponce J, Woodman G, Swain J, et al. REDUCE Pivotal Trial Investigators. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis 2015;11(4): 874-81.
26. López-Nava G, Bautista-Castaño I, Jimenez-Baño A, et al. Dual intragastric balloon: single ambulatory center Spanish experience with 60 patients in endoscopic weight loss management. Obes Surg 2015; 25(12): 2263-7.
27. Machytka E, Klvana P, Kornbluth A, et al. Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management. Obes Surg 2011; 21: 1499-507.
28. Brooks J, Srivastava ED, Mathus-Vliegen EM. One-year adjustable intragastric balloons: results in 73 consecutive patients in the U.K. Obes Surg 2014; 24(5): 813-9.
29. De Castro ML, Morales MJ, Del Campo V, et al. Efficacy, safety, and tolerante of two types of intragastric balloons placed in obese subjects: a double-blind comparative study. Obes Surg 2010; 20(12): 1642-6.
30. Forestieri P, De Palma GD, Formato A, et al. Heliosphere Bag in the treatment of severe obesity: preliminary experience. Obes Surg 2006; 16(5): 635-7.
31. Lecumberri E, Krekshi W, Matía P, et al. Effectiveness and safety of air-filled Balloon Heliosphere BAG in 82 consecutive obese patients. Obes Surg 2011; 21(10): 1508-12.
32. Sciumè C, Geraci G, Pisillo F, et al. Role of intragastric air filled ballon (Heliosphere bag) in severe obesity. Personal experience. Ann Ital Chir 2009; 80(2): 113-7.
33. Trande P, Mussetto A, Mirante VG, et al. Efficacy, tolerance and safety of new intragastric airfilled balloon (Heliosphere BAG) for obesity: the experience of 17 cases. Obes Surg 2010; 20(9): 1227-30.
34. Machytka E, Chuttani R, Bojkova M, et al. Elipse™, a Procedureless Gastric Balloon for Weight Loss: a Proof-of-Concept Pilot Study. Obes Surg 2015 Aug 8. [Epub ahead of print].
35. Mion F, Ibrahim M, Marjoux S, et al. Swallowable Obalon® gastric balloons as an aid for weight loss: a pilot feasibility study. Obes Surg 2013; 23(5): 730-3.
36. Nobili V, Corte CD, Liccardo D, et al. Obalon intragastric balloon in the treatment of paediatric obesity: a pilot study. Pediatr Obes 2015; 10(5): e1-4.
37. Carvalho GL, Barros CB, Okazaki M, et al. An improved intragastric balloon procedure using a new balloon: preliminary analysis of safety and efficiency. Obes Surg 2009; 19(2): 237-42.
38. Bužga M, Evžen M, Pavel K, et al. Effects of the intragastric balloon MedSil on weight loss, fat tissue, lipid metabolism, and hormones involved in energy balance. Obes Surg 2014; 24(6): 909-15.
39. Topazian M, Camillero M, De la Mora-Levy J, et al. Endoscopic ultrasound-guided gastric botulinum toxin injections in obese subjects: a pilot study. Obes Surg 2008; 18(4): 401-7.
40. Foschi D, Lazaron M, Sangaletti O, et al. Effects of intramural administration of Botulinum Toxin A on gastric emptying and eating capacity in obese patients. Dig Liver Dis 2008; 40(8): 667-72.
41. Foschi D, Corsi F, Lazzaroni M, et al. Treatment of morbid obesity by intraparietogastric administration of botulinum toxin: a randomized, double-blind, controlled study. Int J Obes (Lond) 2007; 31(4): 707-12.
42. Mittermair R, Keller C, Geibel J. Intragastric injection of botulinum toxin for the treatment of obesity. Obes Surg 2007; 17(6): 732-6.
43. Júnior AC, Savassi-Rocha PR, Coelho LG, et al. Botulinum A toxin injected into the gastric wall for the treatment of class III obesity: a pilot study. Obes Surg 2006; 16(3): 335-43.
44. Albani G, Petroni ML, Mauro A, et al. Safety and efficacy of therapy with botulinum toxin in obesity: a pilot study. J Gastroenterol 2005; 40(8): 833-5.
45. Gui D, Mingrone G, Valenza V, et al. Effect of botulinum toxin antral injection on gastric emptying and weight reduction in obese patients: a pilot study. Aliment Pharmacol Ther 2006; 23: 675-80.
46. García-Compean D, Mendoza-Fuerte E, Martínez JA, et al. Endoscopic injection of botulinum toxin in the gastric antrum for the treatment of obesity. Results of a pilot study. Gastroenterol Clin Biol 2005; 29(8-9): 789-91.
47. Bang CS, Baik GH, Shin IS, et al. Effect of intragastric injection of botulinum toxin A for the treatment of obesity: a meta-analysis and meta-regression. Gastrointest Endosc 2015; 81(5): 1141-9.
48. Osio M, Mailland E, Muscia F, et al. Botulinum neurotoxin-A does not spread to distant muscles after intragastric injection: A double-blind single-fiber electromyography study. Muscle Nerve 2010; 42(2): 165-9.
49. Espinet Coll E, Nebreda Durán J, Gómez Valero JA, et al. Tratamiento endoscópico secuencial de la obesidad (Apollo®, Argon y toxina botulínica) tras fracaso quirúrgico. XXXVII Jornada Nacional de la Sociedad Española de Endoscopia Digestiva. Zaragoza, 12-14 de Noviembre de 2015.
50. Espinós JC, Turró R, Mata A, et al. Early experience with the Incisionless Operating Platform (IOP) for the treatment of obesity: the Primary Obesity Surgery Endolumenal (POSE) procedure. Obes Surg 2013; 23(9): 1375-83.
51. Espinós JC, Delgado-Aros S, Turró R, et al. Gastrointestinal physiological changes and their relationship to weight loss following the POSE procedure. Obes Surg 2015; 4(9): 1863-8.
52. López-Nava G, Bautista-Castaño I, Jimenez A, et al. The Primary Obesity Surgery Endolumenal (POSE) procedure: one-year patient weight loss and safety outcomes. Surg Obes Relat Dis 2015; 11(4): 861-5.
53. Miller K, Turró R, Greve JW, et al. MILEPOST Multicenter randomized controlled trial: 12-month weight loss and satiety outcomes after POSE SM vs. medical therapy. Obes Surg 2016; Jul 28. [Epub ahead of print].
54. Espinet Coll E, Nebreda Durán J, Gómez Valero JA, et al. Reducción gástrica endoscópica tipo P.O.S.E. ¿Es posible su reconversión quirúrgica laparoscópica? XXXV Jornada Nacional de la Sociedad Española de Endoscopia Digestiva. Madrid, Noviembre 2013.
55. Abu Dayyeh BK, Rajan E, Gostout CJ. Endoscopic sleeve gastroplasty: a potential endoscopic alternative to surgical sleeve gastrectomy for treatment of obesity. Gastrointest Endosc 2013; 78(3): 530-5.
56. Abu Dayyeh BK, Acosta A, Camilleri M, et al. Endoscopic sleeve gastroplasty alters gastric physiology and induces loss of body weight in obese individuals. Clin Gastroenterol Hepatol 2017; 15(1): 37-43.
57. Sharaiha RZ, Kumta NA, Saumoy M, et al. Endoscopic Sleeve Gastroplasty Significantly Reduces Body Mass Index and Metabolic Complications in Obese Patients. Clin Gastroenterol Hepatol 2017, doi: 10.1016/j.cgh.2016.12.012.
58. López-Nava G, Bautista-Castaño I, Fernández-Corbelle JP, et al. Gastroplastia endoscópica en manga (método Apollo): nuevo abordaje en el tratamiento endoscópico de la obesidad. Rev Esp Enferm Dig 2016; 108: 201-206.
59. López-Nava G, Galvão MP, da Bautista-Castaño I, et al. Endoscopic sleeve gastroplasty for the treatment of obesity. Endoscopy 2015; 47(5): 449-52.
60. Sharaiha RZ, Kedia P, Kumta N, et al. Initial experience with endoscopic sleeve gastroplasty: technical success and reproducibility in the bariatric population. Endoscopy 2015; 47(2): 164-6.
61. López-Nava G, Galvão MP, Bautista-Castaño I,, et al. Endoscopic sleeve gastroplasty: how I do it?. Obes Surg 2015; 25(8): 1534-8.
62. López-Nava G, Galvao M, Bautista-Castaño I, et al. Endoscopic sleeve gastroplasty with 1-year follow-up: factors predictive of success. Endosc Int Open 2016; 4(2): E222–E227.
63. Espinet Coll E, Nebreda Durán J, Gómez Valero JA, et al. Concordancia clínico-radiológica en pacientes obesos sometidos a gastroplastia vertical endoscópica (Método Apollo®). Endoscopy 2015; 47-P_011. DOI: 10.1055/s-0035-1566018.
64. Espinet Coll E, López-Nava Breviere G, García Ruiz de Gordejuela A, et al. First comparative study of efficacy and safety of endoscopic and surgical gastric bariatric restrictive procedures at 1 year of follow-up. IFSO. Río de Janeiro, Brasil, 2016.
65. Fishman E, Melanson D, Lamport R, et al. A novel endoscopic delivery system for placement of a duodenal-jejunal implant for the treatment of obesity and type 2 diabetes. Conf Proc IEEE Eng Med Biol Soc 2008; 2501-3.
66. Gersin KS, Keller JE, Stefanidis D, et al. Duodenal-jejunal bypass sleeve: a totally endoscopic device for the treatment of morbid obesity. Surg Innov 2007; 14(4): 275-8.
67. Gersin KS, Rothstein RI, Rosenthal RJ, et al. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc 2010; 71(6): 976-82.
68. Schouten R, Rijs CS, Bouvy ND, et al. A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery. Ann Surg 2010; 251(2): 236.
69. Rodríguez-Grunert L, Galvao Neto MP, Alamo M, et al. First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve. Surg Obes Relat Dis 2008; 4: 55-9.
70. Espinet Coll E, García Ruiz de Gordejuela A, Pujol Gebelli J, et al. By-pass duodeno-yeyunal endoscópico (Endobarrier®) en pacientes con obesidad leve y diabetes compleja. Resultados preliminares. Endoscopy 2015; 47 - P_005. DOI: 10.1055/s-0035-1566012.
71. Escalona A, Pimentel F, Sharp A, et al. Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal-jejunal bypass liner. Ann Surg 2012; 255(6):1080-5.
72. Rohde U, Hedbäck N, Gluud LL, et al. Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2016; 18(3):300-5.
73. Pujol Gebelli J, García Ruiz de Gordejuela A, Casajoana Badía A, et al. Utilización del bypass duodenoyeyunal endoscópico para el tratamiento de pacientes con obesidad grado I y diabetes mellitus tipo 2. J. Cir Esp 2014 (Espec Congr): 253.
74. Vilarrasa N, de Gordejuela AG, Casajoana A, et al. Endobarrier in grade I obese patients with long-standing type 2 diabetes: role of gastrointestinal hormones in glucose metabolism. Obes Surg 2016; Jul 28. [Epub ahead of print].
75. Maggi U, Formiga A, Lauro R. Hepatic abscess as a complication of duodenal-jejunal bypass sleeve system and review of the literature. Surg Obes Relat Dis 2016; 12(5):e47-50. doi: 10.1016/j.soard.2016.02.018. Epub 2016 Feb 23.
76. Espinet Coll E, Pujol Gebelli J, García Ruiz de Gordejuela A, et al. Cholecystitis and duodenal fistula as Endobarrier®-associated complications. Minimally invasive treatment. Rev Esp Enferm Dig 2015; 107(3): 183-4.
77. Rumbaut R, Horgan S, Swain P, et al. A single center feasibility trial of the safety and efficacy of the ValenTx Endo Bypass system in obese subjects. Hospital San José. Monterrey. Méjico 2010 (study ongoing).
78. Sandler BJ, Rumbaut R, Swain CP, et al. One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for morbid obesity. Surg Endosc 2015; 29(11): 3298-303.
79. Sullivan S, Stein R, Jonnalagadda S, et al. Aspiration therapy leads to weight loss in obese subjects: a pilot study. Gastroenterology 2013; 145(6): 1245-52.
80. Forssell H, Norén E. A novel endoscopic weight loss therapy using gastric aspiration: results after 6 months. Endoscopy 2015; 47(1): 68-71.
81. Powers PS, Rosemurgy A, Boyd F, et al. Outcome of gastric restriction procedures: weight, psychiatric diagnoses, and satisfaction. Obes Surg 1997; 7:471-477.
82. Christou N, Look D, Maclean L. Weight gain after short- and long –limb gastric bypass in patients followed for more than 10 years. Ann Surg 2006; 244: 734-740.
83. Sjostrom L, Lindroos A, Peltonem M, et al. Lifestyle, diabetes, and cardiovascular riks factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-2693.
84. Schwartz R, Strodel W, Simpson W, et al. Gastric bypass revision: lessons learned from 920 cases. Surgery 1988; 104: 806-812.
85. Abu Dayyeh BK, Lautz DB, Thompson CC. Gastrojejunal stoma diameter predicts weight regain after Roux-en-Y gastric bypass. Clin Gastroenterol Hepatol 2011; 9: 228-233.
86. Ryou M, Mullady DK, Lautz DB, et al. Pilot study evaluating technical feasibility and early outcomes of second-generation endosurgical platform for treatment of weight regain after gastric bypass surgery. Surg Obes Relat Dis 2009; 5(4): 450-4.
87. Mullady DK, Lautz DB, Thompson CC. Treatment of weight regain after gastric bypass surgery when using a new endoscopic platform: initial experience and early outcomes (with video). Gastrointest Endosc 2009; 70(3): 440-4.
88. Espinet E, López-Nava G, Nebreda J, et al. Reparación endoscópica de la cirugía de la obesidad (R.E.T.O., método Apollo). Resultados preliminares. Semana de las Enfermedades Digestivas. Sevilla, Junio 2015.
89. Changela K, Ofori E, Duddempudi S, et al. Peroral endoscopic reduction of dilated gastrojejunal anastomosis after bariatric surgery: Techniques and efficacy. World J Gastrointest Endosc 2016; 25;8(4): 239-43.
90. Gitelis M, Ujiki M, Farwell L, et al. Six month outcomes in patients experiencing weight gain after gastric bypass who underwent gastrojejunal revision using an endoluminal suturing device. Surg Endosc 2015; 29(8): 2133-40.
91. Jirapinyo Slattery J, Ryan MB, Abu Dayyeh BK, et al. Evaluation of an endoscopic suturing device for transoral outlet reduction in patients with weight regain following Roux-en-Y gastric bypass. Endoscopy 2013; 45(7): 532-6.
92 Kumar N, Thompson CC. Transoral outlet reduction for weight regain after gastric bypass: long-term follow-up. Gastrointest Endosc 2016; 83(4):776-9.
93. Espinet Coll E, Nebreda J, López-Nava G, et al. Estudio multicéntrico de seguridad en el tratamiento endoscópico de la obesidad. Endoscopy 2014; 46 - CO_020. DOI: 10.1055/s-0034-1393744. Rev Esp Enferm Dig 2017 (in press).